Saturday, October 31, 2026

North Korea Fixes Broken Warship, Calls It a ‘Miracle’ of Teamwork

North Korea highlights its military-civilian cooperation in restoring the Kang Kon destroyer and infrastructure projects in Nampo.

China’s DeepSeek Launches Giant AI Model to Take on OpenAI

Chinese AI firm DeepSeek launches DeepSeek-R1-0528, a 685 billion parameter model enhancing reasoning and code generation capabilities.

Rosé’s ‘APT.’ Breaks Records, Becomes Highest-Charting Song by K-pop Female Artist

Rosé of BLACKPINK makes history as "APT." climbs to No. 3 on Billboard's Hot 100, setting a record for K-pop female artists.

Health

Unlock Your Health: Discover the New AI-Powered BioAge and Health Coach Services from DaNaA Data

Daewoo Group's AI health data firm, DaNaA Data, launched a service analyzing biological age, disease risk, and health check results.

How the New Medical School in Namwon Can Transform Regional Healthcare: Insights from Lawmaker Park Ji-won

Defining school locations alone won't solve local healthcare issues; deeper strategies are needed for effective solutions.

Ardens Lifescience Triumphs: How a Korean Startup Won 175,000 USD at MedTech Innovator APAC 2026

Adenz Life Sciences wins a global medical device competition, earning a prize of 175,000 USD.

Unlocking the Future of Healthcare: Daewoong’s AI-Powered Smart Hospital at AI EXPO MARS 2026

Daewoong Pharmaceutical introduces an AI-based smart hospital model for monitoring, diagnosis, testing, and rehabilitation.

10 Years of Excellence: Seoul’s APLAR Center Hosts International Rheumatology Training for Young Specialists

Seoul St. Mary's Hospital's Rheumatology Center held an international training program for foreign experts on October 27 and 26.
Latest

HLB Cholangiocarcinoma Drug FDA Decision Due in 3 Days: No Additional Review Issues Reported

HLB’s bile duct cancer drug lirafugratinib is three days away from its FDA decision, with no additional review or manufacturing-site issues reported so far, keeping attention focused on the U.S. approval outcome.

Lecanemab Shows Manageable Safety Profile in Korean Patients

A real-world analysis of Korean patients treated with lecanemab found that most infusion-related reactions and amyloid-related imaging abnormalities (ARIA) were mild or asymptomatic, while baseline MRI assessment and regular monitoring remained important.

Daewoong Pharma Unveils First Patient Data From Phase 2 Trial of Pulmonary Fibrosis Drug Bersiporocin

Daewoong Pharmaceutical has presented baseline characteristics for all 104 patients enrolled in the global Phase 2 trial of bersiporocin, its investigational treatment for idiopathic pulmonary fibrosis

Matica Bio Partners With Bondwell Technologies to Develop Next-Generation Protein Manufacturing Processes

Matica Bio, the U.S. subsidiary of CHA Biotech, will provide process optimization services to Bondwell Technologies to support production and commercialization of next-generation protein biomaterials.

From Research Breakthroughs to New Drugs: Helping K-Drug Candidates Reach Global Markets

South Korea is strengthening support across the commercialization process to help domestically discovered drug candidates move beyond licensing deals and become globally developed medicines.

I Started a Company to Solve Patient Problems. For This Doctor-Founder, It Took Seven Years to Break Through

AITRICS CEO Kim Kwang-jun spent seven to eight years turning a clinical need he identified as a geriatrician into an AI medical product that could actually be used in hospitals.

ST Pharm Secures Record $66.1 Million Oligonucleotide API Supply Contract

ST Pharm has won a $66.1 million oligonucleotide drug substance supply contract from a global U.S.-based biotech company, marking its largest single oligonucleotide contract to date.

Unlocking the Future: How IVL3004’s Monthly Injection Revolutionizes Addiction Treatment

Inventage Lab receives U.S. patent approval for a monthly drug addiction treatment, aiming for clinical trials and global commercialization.

HLB’s LYRFIGTU: What Does FDA’s Conditional Acceptance Mean for Biliary Cancer Treatment?

HLB's new bile duct cancer drug candidate, Liraglutide, is expected to be named LYRFIGTU in the U.S., with FDA approval on September 25.

GCC2005: Breakthrough CAR-NK Therapy Shows 62.5% Response Rate in Clinical Trial

GC Cell announced interim results of its clinical trial for GCC2005 (CD5 CAR-NK) presented at ICBMT 2026 on September 17.

2026 Citizen Human Rights Award: Honoring Activism and Legal Excellence in South Korea

Human rights advocate Sek Al Mamoon and the Korean Women's Labor Association recognized for their work on migrant workers and refugee issues.

K-Medical Excellence: How Seoul Asan Hospital Dominates Global Rankings in 2027

Major South Korean hospitals ranked among the world's best specialized hospitals, showcasing the competitiveness of K-Medicine.

97-Year-Old Cancer Survivor Thrives After Robotic Surgery: A Breakthrough in Elderly Care

A 97-year-old gastric cancer patient received robotic surgery from Professor Kim at Catholic University, expressing heartfelt gratitude for a new lease on life.

Alteogen Wins Japanese Marketing Approval for Keytruda SC Using ALT-B4

Alteogen has secured Japanese manufacturing and marketing approval for MSD’s subcutaneous Keytruda formulation using Alteogen’s ALT-B4 technology, expanding the drug’s global commercialization footprint.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.